Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 11/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 8/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MYLK | Q15746 | 1/20 | 0.43 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330258 | 0.87 | TMPRSS4 (0.43) | TMPRSS4MEN1KMT2A | |
| SCHEMBL331571 | 0.84 | NR1H4 (0.45) | KCNMA1MEN1KMT2AMAP4K5 | |
| SCHEMBL3475591 | 0.84 | RAB9A (0.56) | MEN1KMT2A | |
| SCHEMBL6101128 | 0.83 | MAPT (0.42) | KCNMA1MEN1KMT2AMAP4K5 | |
| SCHEMBL330170 | 0.81 | TMPRSS4 (0.51) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL6103187 | 0.77 | ALDH1A1 (0.45) | MEN1KMT2A | |
| SCHEMBL6102790 | 0.76 | LRRK2 (0.41) | KCNMA1MEN1KMT2A | |
| SCHEMBL15916250 | 0.75 | RAB9A (0.67) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL331430 | 0.72 | MAPT (0.53) | TMPRSS4MEN1KMT2A | |
| SCHEMBL329927 | 0.72 | DHODH (0.54) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | KCNMA1 3127/4885P2RX1 4560/4885TMPRSS4 2764/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | KCNMA1 2192/4885P2RX1 4850/4885TMPRSS4 3353/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | KCNMA1 197/4885P2RX1 2927/4885TMPRSS4 4304/4885 |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | KCNMA1 680/4885P2RX1 2507/4885TMPRSS4 4278/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3082/4885P2RX1 1459/4885TMPRSS4 1813/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885TMPRSS4 1647/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885TMPRSS4 1647/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | KCNMA1 1584/4885P2RX1 3156/4885TMPRSS4 3386/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | KCNMA1 201/4885P2RX1 2425/4885TMPRSS4 4402/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | KCNMA1 3082/4885P2RX1 3644/4885TMPRSS4 3984/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | KCNMA1 190/4885P2RX1 2389/4885TMPRSS4 4368/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | KCNMA1 2705/4885P2RX1 2316/4885TMPRSS4 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.